Hedera Dx is dedicated to transforming oncology by providing cutting-edge liquid biopsy solutions that improve patient experiences, outcomes, and journeys, as well as healthcare professional experiences, while facilitating the prescription, discovery, and development of the next breakthrough precision oncology therapies.

Hedera Dx aims to make liquid biopsies globally accessible for patients by enabling routine use of validated liquid biopsies in-house without compliance, bioinformatics, and reporting hurdles at all disease stages. The company adopts both a customer- and a patient-centric approach, integrating patient-reported outcomes (PROs), patient-reported experience measures (PREMs), patient groups, and customer feedback to deliver products and services matching the needs of those who need it most.

They provide fast, locally CE-IVDR compliant, and clinically actionable NGS-based liquid biopsy solutions for hospital laboratories. Hedera Dx's approach looks to become a global provider of analytically and clinically validated liquid biopsy tests processed in daily practice, in accordance with guidelines and regulatory-approved cancer therapy options.

Founded in Switzerland in 2021 by Tommi Lehtonen (CEO), Damien Lapray (CCO), and Christian Meisel (CMO), the team is committed to revolutionizing oncology by making liquid biopsies a standard practice worldwide. Their backgrounds span genetics entrepreneurship, hospital laboratory expertise, and precision oncology clinical experience.

Hedera Dx is headquartered at Route de la Corniche 5, Bâtiment Alanine, Epalinges, Vaud 1066, Switzerland.

https://www.linkedin.com/company/hedera-dx/

Open positions and career opportunities can be found at their dedicated job portal: https://hederadx.teamtailor.com/jobs. The company seeks talented individuals passionate about simplifying cancer testing and joining their mission.